BMO Capital on Pfizer (PFE): 'Results are positive for tucatinib commercial expansion'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $30.00 price target on Pfizer (NYSE: PFE).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
